Angiostatin is a 38 kDa internal fragment of plasminogen comprising kringle domains 1 through 4, first identified in 1994 by Michael O'Reilly in Judah Folkman's laboratory at Children's Hospital Boston. It was discovered as a circulating factor produced by primary tumors that suppressed the growth of distant metastases — a phenomenon known as concomitant tumor resistance.

Overview

Angiostatin is generated by proteolytic cleavage of plasminogen, the zymogen precursor of the fibrinolytic enzyme plasmin. The kringle domains of plasminogen are triple-disulfide-bonded, autonomously folding structures of approximately 80 amino acids each. Angiostatin encompasses kringles 1-4 (K1-4), though fragments containing kringles 1-3 (K1-3) or individual kringles also possess anti-angiogenic activity, with kringle 5 showing particularly potent independent activity. The proteolytic generation of angiostatin from plasminogen can be mediated by several enzymes, including matrix metalloproteinases (MMP-2, MMP-9, MMP-12), elastase, cathepsin D, and plasmin itself through autoproteolysis. Tumor-associated macrophages are a major source of the metalloelastase (MMP-12) responsible for angiostatin generation in vivo.

Folkman's discovery of angiostatin emerged from a longstanding clinical observation: primary tumors often suppress the growth of their metastases, and surgical removal of the primary tumor can trigger explosive metastatic growth. O'Reilly and Folkman demonstrated that Lewis lung carcinoma in mice produced a circulating inhibitor that maintained distant metastases in a dormant, avascular state. Isolation and characterization of this inhibitor revealed it to be a fragment of plasminogen — angiostatin.

Mechanism of Action

Angiostatin exerts its anti-angiogenic effects through multiple mechanisms targeting endothelial cells:

• ATP Synthase Binding: Angiostatin binds to the alpha/beta subunits of ATP synthase expressed on the endothelial cell surface. This cell-surface ATP synthase generates extracellular ATP that supports endothelial cell proliferation and migration. Angiostatin binding inhibits this catalytic activity, reducing extracellular ATP levels and suppressing endothelial proliferation. Moser et al. (1999) — Proc. Natl. Acad. Sci. USA

• Endothelial Cell Apoptosis: Angiostatin induces apoptosis selectively in proliferating endothelial cells through activation of caspase-mediated pathways. This selectivity for activated (angiogenic) endothelium over quiescent endothelium provides a therapeutic window — established vasculature is relatively spared while new vessel formation is inhibited. Claesson-Welsh et al. (1998) — Proc. Natl. Acad. Sci. USA

• Integrin αvβ3 Interaction: Angiostatin interacts with integrin αvβ3, a key adhesion receptor for angiogenesis. This interaction disrupts endothelial cell adhesion, migration, and survival signaling through the integrin-linked kinase and focal adhesion kinase (FAK) pathways. Tarui et al. (2001) — J. Biol. Chem.

• Angiomotin Binding: Angiostatin binds angiomotin, a cell-surface protein that mediates endothelial cell migration. This interaction inhibits angiomotin-dependent migration and tube formation. Troyanovsky et al. (2001) — J. Cell Biol.

• Hepatocyte Growth Factor Antagonism: Angiostatin binds hepatocyte growth factor (HGF) and blocks its interaction with the c-Met receptor, inhibiting HGF-induced endothelial cell proliferation, migration, and angiogenesis. Sengupta et al. (2003) — Cancer Res.

• Plasminogen Activator Inhibition: By competing with plasminogen for cell-surface binding sites, angiostatin indirectly inhibits pericellular plasmin generation, which is required for extracellular matrix degradation during endothelial cell invasion and new vessel formation.

Reconstitution Calculator

Research

Safety Profile

Recombinant human angiostatin demonstrated a favorable safety profile in phase I clinical trials. The most common adverse effects were mild and included injection-site reactions (subcutaneous administration), mild nausea, fatigue, and transient elevation of liver transaminases. No dose-limiting toxicities were identified at doses up to 60 mg/m²/day in phase I studies. Wound healing impairment is a theoretical concern with all anti-angiogenic agents, though this was not a prominent clinical finding in angiostatin trials, possibly due to its selectivity for proliferating endothelium. Unlike VEGF pathway inhibitors (bevacizumab, sorafenib), angiostatin did not produce hypertension, proteinuria, or thromboembolic events in clinical studies, suggesting a distinct safety profile related to its different mechanism. Immunogenicity was not a significant concern with recombinant human angiostatin, as it is a fragment of human plasminogen. The primary limitation in clinical development was not toxicity but rather insufficient single-agent efficacy at achievable circulating concentrations, compounded by the short half-life requiring frequent or continuous dosing.

Clinical Research Protocols

• Phase I IV protocol (Herbst et al.): Recombinant human angiostatin 15-60 mg/m²/day by daily IV infusion over 15-20 minutes, in 28-day cycles. Pharmacokinetic sampling at multiple timepoints. Disease assessment by imaging every 8 weeks.
• Phase I SC protocol (DeMoraes et al.): Recombinant human angiostatin 0.5-60 mg/m² subcutaneously, dose escalation in cohorts of 3-6 patients. Injection-site monitoring and pharmacokinetic assessment.
• Combination with radiation (preclinical protocol): Angiostatin 50-100 mg/kg/day IP in mice combined with fractionated radiation (2 Gy × 5 fractions). Tumor volume measurement and microvessel density quantification by CD31 immunostaining.
• Combination with chemotherapy: Angiostatin combined with paclitaxel/carboplatin at standard oncologic doses. Monitoring for enhanced myelosuppression or bleeding.
• Biomarker assessments: Circulating angiostatin levels measured by ELISA. Urine and serum VEGF, bFGF, and angiogenin as pharmacodynamic biomarkers. Dynamic contrast-enhanced MRI (DCE-MRI) for tumor perfusion assessment.

Pharmacokinetic Profile